VEEA INC. 8-K

What Happened Veea Inc. announced that Nasdaq approved transferring its common stock and public warrants from The Nasdaq Global Market to The Nasdaq Capital Market, effective April 9, 2026. The company previously received Nasdaq deficiency notices (first issued Sept 29, 2025) for failing to meet the $1.00 minimum bid-price rule and minimum market-value thresholds. Nasdaq granted Veea a second 180‑day compliance period to regain the $1.00 closing bid-price requirement, now running through September 28, 2026.

Key Details

• Nasdaq first notified Veea of non-compliance on Sept 29, 2025 for: the $1.00 minimum bid price, a $15,000,000 minimum market value of publicly held shares (MVPHS), and a $50,000,000 market value of listed securities (MVLS).
• Initial 180‑day cure period expired March 30, 2026; Veea applied to transfer listings on March 27, 2026 and Nasdaq approved the transfer on April 7, 2026, effective April 9, 2026.
• Under the Capital Market transfer, Nasdaq granted an additional 180 days (until Sept 28, 2026) to regain compliance by achieving a closing bid price ≥ $1.00 for at least 10 consecutive business days.
• Trading was uninterrupted and continues under tickers “VEEA” (common stock) and “VEEAW” (warrants). Veea said it may consider actions such as a reverse stock split to cure the deficiency.

Why It Matters The transfer to the Nasdaq Capital Market and the extended cure period give Veea more time to meet Nasdaq’s $1.00 bid-price requirement without an immediate delisting. For investors, the move does not change current trading (same tickers) but signals the company remains under listing risk until it meets the bid-price test or takes corporate actions (e.g., reverse split). If Veea does not regain compliance by Sept 28, 2026, Nasdaq could begin delisting proceedings, which could adversely affect liquidity and share price.